secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001628280-25-014601
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma FY2024 net rev $2.6M; Phase 3 CN trial on track; restructuring cuts spend $30-35M
--------------------------------------------------------------------------------

- XOLREMDI net product revenue $2.6M from May 2024 launch through YE; cost of revenue $0.8M.
- Net loss FY2024 $37.5M (incl. $105M PRV gain); cash $102.8M; pro-forma runway into 1H 2026.
- Phase 3 4WARD trial for chronic neutropenia activated at ~90% sites; full enrollment expected Q3/Q4 2025; top-line data 2H 2026.
- Protocol amendment: enroll only moderate/severe CN (ANC<1000); co-primary endpoint refined to uniform ANC increase ≥500 cells/µL.
- Strategic restructuring reduces annual spend by $30-35M; includes headcount reduction, closing Vienna facility, and right-sizing US team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/0001628280-25-014601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/xfor-20250325.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-014601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer